How long should you wait before concluding that antipsychotic-related sedation isn't going to resolve on its own? A new meta-analysis finally puts a number on it.

Irritability in pediatric ADHD often persists despite stimulant treatment, yet targeted options are limited. Could an NMDA antagonist already sitting on pharmacy shelves offer a safer adjunct? A small pilot trial reports a striking early signal.

Dextromethorphan misuse is common, especially among young people, yet can easily be overlooked by family and healthcare providers alike. This article reviews recognition of toxicity across the four “plateaus,” psychiatric and medical complications, and supportive management strategies—including when to consider benzodiazepines, antipsychotics, or naloxone.

A dextromethorphan-bupropion combo tablet shows promise in treating major depression. The FDA recognized its potential in 2019, so stay tuned for more updates on this novel treatment.

Sublingual dexmedetomidine was found to work effectively and quickly for mild to moderate agitation in patients with bipolar disorder.